Good morning, everyone, and welcome to another working week. We hope the weekend respite was sufficiently distracting, if not relaxing, because that predictable routine of Zoom and Skype meetings has returned. But what can you do? Despite the ongoing tumult, the world keeps spinning. So please join us as we cope with a delicious cup of stimulation. Our choice today is cinnamon dolce, for those tracking such things. Meanwhile, here are a few tidbits to move you along. Hope your day is productive, and do keep in touch. …

Recovered Covid-19 patients in China may still be vulnerable to a mutant form of the pathogen spreading overseas, The South China Morning Post reports. Antibodies found in patients who had been infected with earlier forms of the pathogen failed to neutralize the mutant strain, according to a paper published on A report published last week suggested the D614G mutation has the potential to increase the number of spike proteins on the coronavirus and boost its ability to infect human cells by a factor of 10.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
Sign up to receive a free weekly opinions recap from our community of experts.
Privacy Policy